The role of MGMT polymorphisms rs12917 and rs11016879 in head and neck cancer risk and prognosis

• Authors: Paweł Kiczmer , Alicja Prawdzic Seńkowska , Joanna Strzelczyk , Błażej Szydło , Krzysztof Biernacki , Tadeusz Osadnik , Łukasz Krakowczyk , Zofia Ostrowska
• Languages of publication: EN

Abstracts

EN

Head and neck squamous cell carcinoma (HNSCC) is one of the leading cancers by incidence worldwide. The risk of these cancers is strictly associated with alkylation factors present in tobacco smoke. The crucial role in preventing DNA alkylation is played by O6-methylguanine-DNA methyltransferase (MGMT). Dysfunction or lack of MGMT is associated with an increased risk of cancer. The aim of the study was to assess the influence of MGMT polymorphisms: rs12917 and rs11016879 on HNSCC risk and course. The study consisted of 69 HNSCC patients and 242 healthy individuals. Case samples were taken from resected tumour tissue. The control group comprised samples of epithelial cells collected from mucous membranes using swabs. DNA samples were genotyped by employing the 5' nuclease assay for allelic discrimination using TaqMan SNP Genotyping Assays. The significance between distributions of genotypes and alleles was tested using Pearson's χ2 test analysis. Our results indicated that the MGMT rs12917 TT genotype increases the risk of HNSCC. The MGMT rs11016879 AG genotype and A allele were associated with increased HNSCC risk. We noted higher risk of nodal metastasis in rs11016879 AA homozygotes. Mechanisms leading to MGMT enzymatic defect are unknown and hence further studies need to be carried out. Our data suggest that the examined polymorphisms may be considered as potential prognostic factors for HNSCC risk and outcome. Further studies are necessary to verify our results.

Keywords

EN

MGMT; head and neck cancer; polymorphism; rs12917; rs11016879

• Publisher: Polish Biochemical Society
• Journal: Acta Biochimica Polonica
• Year: 2018
• Volume: 65
• Issue: 1
• Pages: 87-92

Dates

published

2018

received

2017-05-17

revised

2017-10-31

accepted

2017-12-18

(unknown)

2018-01-25

Contributors

author

Paweł Kiczmer

• Department of Medical and Molecular Biology, School of Medicine with the Division of Dentistry, Medical University of Silesia in Zabrze, Katowice, Poland

author

Alicja Prawdzic Seńkowska

• Department of Medical and Molecular Biology, School of Medicine with the Division of Dentistry, Medical University of Silesia in Zabrze, Katowice, Poland

author

Joanna Strzelczyk

• Department of Medical and Molecular Biology, School of Medicine with the Division of Dentistry, Medical University of Silesia in Zabrze, Katowice, Poland

author

Błażej Szydło

• Department of Medical and Molecular Biology, School of Medicine with the Division of Dentistry, Medical University of Silesia in Zabrze, Katowice, Poland

author

Krzysztof Biernacki

• Department of Medical and Molecular Biology, School of Medicine with the Division of Dentistry, Medical University of Silesia in Zabrze, Katowice, Poland

author

Tadeusz Osadnik

• 2nd Department of Cardiology and Angiology, Silesian Center for Heart Disease, Zabrze, Poland
• Genomics Laboratory, Kardio-Med Silesia Science and Technology Park, Zabrze, Poland

author

Łukasz Krakowczyk

• Department of Oncological and Reconstructive Surgery, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland

author

Zofia Ostrowska

• Department of Medical and Molecular Biology, School of Medicine with the Division of Dentistry, Medical University of Silesia in Zabrze, Katowice, Poland

References

• Bartkowski, SB (1996) Chirurgia szczękowo-twarzowa. Ages, Kraków 33-34 (in Polish)
• Burusapat C, Jarungroongruangchai W, Charoenpitakchai M (2015) Prognostic factors of cervical node status in head and neck squamous cell carcinoma. World J Surg Oncol 13: 51. doi: 10.1186/s12957-015-0460-6.
• Czech A, Fedyunin I, Zhang G, Ignatova Z (2010) Silent mutations in sight: Co-variations in tRNA abundance as a key to unravel consequences of silent mutations. Mol Biosyst 6: 1767-1772.
• Doecke J, Zhao ZZ, Pandeya N, Sadeghi S, Stark M, Green AC, Hayward NK, Webb PM, Whiteman DC (2008) Polymorphisms in MGMT and DNA repair genes and the risk of esophageal adenocarcinoma. Int J Cancer 123: 174-180. doi: 10.1002/ijc.23410.
• Du L, Wang H, Xiong T, Ma Y, Yang J, Huang J, Zeng D, Wang X, Huang H (2013) The polymorphisms in the MGMT gene and the risk of cancer. A meta-analysis. Tumour Biol 34: 3227-3237. doi: 10.1007/s13277-013-0893-x.
• Egyhazi S, Ma S, Smoczynski K, Hansson J, Platz A, Ringborg U (2002) Novel O6-methylguanine-DNA methyltransferase SNPs: a frequency comparison of patients with familial melanoma and healthy individuals in Sweden. Hum Mutat 20: 408-409. doi: 10.1002/humu.9078.
• Fogli A, Chautard E, Vaurs-Barriere C, Pereira B, Muller-Barthelemy M, Court F, Biau J, Pinto AA, Kemeny JL, Khalil T, Karayan-Tapon L, Verrelle P, Costa BM, Arnaud P (2016) The tumoral A genotype of the MGMT rs34180180 single-nucleotide polymorphism in aggressive gliomas is associated with shorter patients' survival. Carcinogenesis 37: 169-176. doi: 10.1093/carcin/bgv251.
• Hall J, Hashibe M, Boffetta P, Gaborieau V, Moullan N, Chabrier A, Zaridze D, Shangina O, Szeszenia-Dabrowska N, Mates D, Janout V, Fabianova E, Holcatova I, Hung RJ, McKay J, Canzian F, Brennan P (2007) The association of sequence variants in DNA repair and cell cycle genes with cancers of the upper aerodigestive tract. Carcinogenesis 28: 665-671. doi: 10.1093/carcin/bgl160.
• Hashibe M, Brennan P, Chuang SC, Boccia S, Castellsague X, Chen C, Curado MP, Dal Maso L, Daudt AW, Fabianova E, Fernandez L, Wunsch-Filho V, Franceschi S, Hayes RB, Herrero R, Kelsey K, Koifman S, La Vecchia C, Lazarus P, Levi F, Lence JJ, Mates D, Matos E, Menezes A, McClean MD, Muscat J, Eluf-Neto J, Olshan AF, Purdue M, Rudnai P, Schwartz SM, Smith E, Sturgis EM, Szeszenia-Dabrowska N, Talamini R, Wei Q, Winn DM, Shangina O, Pilarska A, Zhang ZF, Ferro G, Berthiller J, Boffetta P (2009) Interaction between tobacco and alcohol use and the risk of head and neck cancer. Pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Cancer Epidemiol Biomarkers Prev 18: 541-550. doi: 10.1158/1055-9965.EPI-08-0347.
• Huang WY, Olshan AF, Schwartz SM, Berndt SI, Chen C, Llaca V, Chanock SJ, Fraumeni JF, Hayes RB (2005) Selected genetic polymorphisms in MGMT, XRCC1, XPD, and XRCC3 and risk of head and neck cancer: A pooled analysis. Cancer Epidemiol Biomarkers Prev 14: 1747-1753. doi: 10.1158/1055-9965.EPI-05-0162.
• Jacob R, Shafiei N, Nagel G, Welkoborsky HJ, Mann W, Kaina B (2010) MGMT activity in mucosal epithelium and squamous cell carcinoma of the head and neck. Anticancer Res 30: 2561-2566.
• Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, Gottesman MM (2007) A 'silent' polymorphism in the MDR1 gene changes substrate specificity. Science 315: 525-528. doi: 10.1126/science.1135308.
• Komar AA, Lesnik T, Reiss C (1999) Synonymous codon substitutions affect ribosome traffic and protein folding during in vitro translation. FEBS Lett 462: 387-391. doi: 10.1016/S0014-5793(99)01566-5.
• Kordek R, Jassem J, Jeziorski A, Kornafel J, Krzakowski M, Pawlęga J (2013) Onkologia. Podręcznik dla studentów. Via Medica, Gdańsk, 2013. 146-157 (in Polish)
• Kreimer AR, Clifford GM, Boyle P, Franceschi S (2005) Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 14: 467-475. doi: 10.1158/1055-9965.EPI-04-0551.
• Krzakowski M, Warzocha K (2013) Nowotwory nabłonkowe narządów głowy i szyi. In: Zalecenia postępowania diagnostyczno-terapeutycznego w nowotworach złośliwych. 2013 Via Medica, Gdańsk 5-13 (in Polish)
• Moore LE, Brennan P, Karami S, Menashe I, Berndt SI, Dong LM, Meisner A, Yeager M, Chanock S, Colt J, Schwartz K, Davis F, Zaridze D, Mattveev V, Janout V, Kollarova H, Bencko V, Navratilova M, Szeszenia-Dabrowska N, Mates D, Holcatova I, Boffetta P, Chow WH, Rosenberg PS, Rothman N (2009) Apolipoprotein E/C1 locus variants modify renal cell carcinoma risk. Cancer Res 69: 8001-8008 (Suppl 1). doi: 10.1158/0008-5472.CAN-09-1734.
• Leemans CR, Tiwari R, Nauta JJ, Waal IV, Snow GB (1994) Recurrence at the primary site in head and neck cancer and the significance of neck lymph node metastases as a prognostic factor. Cancer 73: 187-190. doi: 10.1002/1097-0142(19940101)73:1<187::AID-CNCR2820730132>3.0.CO;2-J.
• Ma WJ, Lv GD, Zheng ST, Huang CG, Liu Q, Wang X, Lin RY, Sheyhidin I, Lu XM (2010) DNA polymorphism and risk of esophageal squamous cell carcinoma in a population of North Xinjiang, China. World J Gastroenterol 16: 641-647.
• Maier H, Dietz A, Gewelke U, Heller WD, Weidauer H (1992) Tobacco and alcohol and the risk of head and neck cancer. Clin Investig 70: 320-327.
• Majchrzak E, Szybiak B, Wegner A, Pienkowski P, Pazdrowski J, Luczewski L, Sowka M, Golusinski P, Malicki J, Golusinski W (2014) Oral cavity and oropharyngeal squamous cell carcinoma in young adults: a review of the literature. Radiol Oncol 48: 1-10. doi: 10.2478/raon-2013-0057.
• Marur S, Forastiere AA (2008) Head and neck cancer: changing epidemiology, diagnosis, and treatment. Mayo Clin Proc 83: 489-501. doi: 10.4065/83.4.489.
• Molina E, Perez-Morales R, Rubio J, Petrosyan P, Cadena LH, Arlt V M, Phillips DH, Gonsebatt ME (2013) The GSTM1null (deletion) and MGMT84rs12917 (Phe/Phe) haplotype are associated with bulky DNA adduct levels in human leukocytes. Mutat Res 758: 62-68. doi: 10.1016/j.mrgentox.2013.09.007.
• Ndiaye C, Mena M, Alemany L, Arbyn M, Castellsagué X, Laporte L, Bosch FX, de Sanjosé S, Trottier H (2014) HPV DNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers. A systematic review and meta-analysis. Lancet Oncol 15: 1319-1331. doi: 10.1016/S1470-2045(14)70471-1.
• Onerci Celebi O, Tezel GG, Hosal AS, Cengiz M, Gullu IH, Hayran M (2016) Detection of O6-methylguanine-DNA methyltransferase gene promoter region methylation pattern using pyrosequencing and the effect of methylation pattern on survival, recurrence, and chemotherapy sensitivity in patients with laryngeal cancer. Pathol Res Pract 212: 456-62. doi: 10.1016/j.prp.2016.02.022.
• Pfeifer GP, Denissenko MF, Olivier M, Tretyakova N, Hecht SS, Hainaut P (2002) Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene 21: 7435-7451. doi: 10.1038/sj.onc.1205803.
• Qiu ZX, Xue F, Shi XF, He X, Ma HN, Chen L, Chen PZ (2014) MGMT Leu84Phe gene polymorphism and lung cancer: a meta analysis. Tumour Biol 35: 4381-4387. doi: 10.1007/s13277-013-1576-3.
• Ragin CC, Modugno F, Gollin SM (2007) The epidemiology and risk factors of head and neck cancer: a focus on human papillomavirus. J Dent Res 86: 104-114.
• Rapkins RW, Wang F, Nguyen HN, Cloughesy TF, Lai A, Ha W, Nowak AK, Hitchins MP, McDonald KL (2015) The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide. Neuro oncol 17: 1589-1598. doi: 10.1093/neuonc/nov064.
• Sawhney M, Rohatgi N, Kaur J, Gupta SD, Deo SV, Shukla NK, Ralhan R (2012) MGMT expression in oral precancerous and cancerous lesions. Correlation with progression, nodal metastasis and poor prognosis. Oral Oncology 43: 515-522. doi: 10.1016/j.oraloncology.2006.05.007.
• Sharma S, Salehi F, Scheithauer BW, Rotondo F, Syro LV, Kovacs K (2009) Role of MGMT in tumor development, progression, diagnosis, treatment and prognosis. Anticancer Res 29: 3759-3768. doi: .
• Shen LX, Basilion JP, Stanton VP Jr (1999) Single-nucleotide polymorphisms can cause different structural folds of mRNA. Proc Natl Acad Sci U S A 96: 7871-7876. doi: .
• Strzelczyk JK, Golabek K, Krakowczyk L, Owczarek AJ (2016) Expression profiles of MGMT, p16, and APC genes in tumor and matching surgical margin from patients with oral squamous cell carcinoma. Acta Biochim Pol 63: 505-509. doi: 10.18388/abp.2015_1204.
• Wibom C, Sjostrom S, Henriksson R, Brannstrom T, Broholm H, Ryden P, Johansen C, Collatz-Laier H, Hepworth S, McKinney PA, Bethke L, Houlston RS, Andersson U, Melin BS (2012) DNA-repair gene variants are associated with glioblastoma survival. Acta Oncol 51: 325-332. doi: 10.3109/0284186X.2011.616284.
• Yu D, Cao T, Han YD, Huang FS (2016) Relationships between MGMT promoter methylation and gastric cancer. A meta-analysis. OncoTargets and Therapy 9: 6049-6057. doi: 10.2147/OTT.S114052.
• Zhang Z, Wang L, Wei S, Liu Z, Wang LE, Sturgis EM, Wei Q (2010) Polymorphisms of the DNA repair gene MGMT and risk and progression of head and neck cancer. DNA Repair 9: 558-566. doi: 10.1016%2Fj.dnarep.2010.02.006.
• Zhong Y, Huang Y, Huang Y, Zhang T, Ma C, Zhang S, Fan W, Chen H, Qian J, Lu D (2010) Effects of O6-methylguanine-DNA methyltransferase (MGMT) polymorphisms on cancer: a meta-analysis. Mutagenesis 25: 83-95. doi: 10.1093/mutage/gep050.
• Ziółkowska E, Biedka M, Windorbska W (2011) Odczyn popromienny u chorych na raka region głowy I szyi: mechanizmy I konsekwencje. Otolaryngologia 10: 147-153 (in Polish)

Identifiers

DOI

10.18388/abp.2017_1613